Core Insights - The focus of PTC has shifted towards both late-stage programs and earlier-stage R&D initiatives, emphasizing the importance of execution in these areas [2] - The company has made a strategic decision to concentrate on small molecule therapies and leverage unique scientific capabilities to develop transformative therapies for patients with high unmet medical needs [2][3] Company Strategy - PTC has restructured its operations to prioritize small molecule splicing platforms, indicating a clear direction in its research and development efforts [3]

PTC Therapeutics (NasdaqGS:PTCT) 2025 R&D Day December 02, 2025 09:30 AM ET Company ParticipantsJeff Trimmer - Head of ResearchChristopher Trotta - SVP of Discovery SplicingMatthew Klein - CEOMayzie Johnston - VP of Global Project LeadTazeen Ahmad - Managing DirectorClara Dong - VP of Equity Research in BiotechnologyAnu Bhattacharya - Head of Splicing ProgramsGena Wang - Managing Director of Biotech Equity ResearchConference Call ParticipantsBrian Cheng - Executive Director and Senior Biotech AnalystJudah F ...